By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.